CRISPR Therapeutics’ Post

We're excited to share that our CEO Dr. Samarth Kulkarni will be speaking on a panel at #AspenIdeasHealth tomorrow (Friday, June 21) at 11:40am MT / 1:40pm ET about ways to expand on the broad potential for the #CRISPR technology. Tune in here: https://bit.ly/4cyAU49 Aspen Ideas

#Listening is this year's theme for #WorldKidneyCancerDay. CRISPR Therapeutics is committed to listening to and learning from people who live with #KidneyCancer. Meet Chuck, an incredible advocate who is living with #RenalCellCarcinoma. Read his inspiring story here: https://bit.ly/3UxwO3n

Today is #WorldSickleCellDay, a day to #ShinetheLightonSickleCell and raise awareness about #SCD and its impact on people around the world. Learn more about #SCD: https://bit.ly/3xpC9mW

We recently volunteered at the One8 Applied Learning Hub Student Showcase, which featured over 1,000 students (grades 5-12) across Massachusetts who presented their STEM and applied learning projects. We had the opportunity to provide feedback to help build on their STEM education. Learn more here about One8 Applied Learning Hub here: https://lnkd.in/ewA9A4Mh #CRISPRTX

We are pleased to announce the promotion of Julianne Bruno, M.B.A., to Chief Operating Officer of CRISPR Therapeutics. Since joining the company in 2019, Julie has been a valuable member of the leadership team and has led important and impactful cross-functional initiatives. Read more here: https://bit.ly/3KdIpRJ

We’re excited to welcome Naimish Patel, M.D., who is joining CRISPR Therapeutics as Chief Medical Officer. Dr. Patel brings extensive drug development experience and proven leadership, which will be critical as we continue to advance our pipeline. Read more here: https://bit.ly/3KdIpRJ

This week, our CEO & Chairman Samarth Kulkarni, PhD, with members of our team and Board of Directors, rang the Opening Bell at the Nasdaq MarketSite Studio in Times Square to celebrate our recent milestones and growth. We’re proud to ring in our success as a company and the impact we can have on people living with serious diseases. Watch the Opening Bell ceremony here: https://bit.ly/4dL3BfE   Photography courtesy of Nasdaq, Inc.

The Precision Health Alliance, a new consortium co-founded by Duke Clinical Research Institute, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Inc., and Verve Therapeutics, launched this week and will focus on innovation in precision medicine and gene editing. Learn more here: phgea.org.

We're thrilled to share that CRISPR Therapeutics will ring the Opening Bell this morning at the Nasdaq MarketSite Studio in Times Square.     We’re excited to commemorate the historic first-ever approval of a CRISPR-based therapy and celebrate innovation as we continue to expand and advance our programs for rare and common diseases.    Join us by tuning in for the livestream here starting at 9:15am ET: https://lnkd.in/eJz78vY